Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | KCNJ6 | P48051 | 4/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 4/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828672 | 0.80 | DEGS1 (0.46) | NTRK1CDK5RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL23719252 | 0.77 | TP53 (0.52) | ROCK2NTRK1CCNE1CDK2ALDH1A1 | |
| SCHEMBL23719197 | 0.77 | KMT2A (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL22828671 | 0.77 | CLK2 (0.49) | ROCK2NTRK1NPC1RAB9AKDM4E | |
| SCHEMBL22050711 | 0.74 | CAMKK1 (0.42) | CCNE1CDK2CDK5 | |
| SCHEMBL22049600 | 0.73 | STING1 (0.40) | CCNE1CDK2CDK5ALDH1A1NPC1 | |
| SCHEMBL23719136 | 0.73 | EPHX1 (0.49) | ROCK2CCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL22050235 | 0.71 | STING1 (0.42) | CCNE1CDK2CDK5 | |
| SCHEMBL22049597 | 0.71 | STING1 (0.42) | CCNE1CDK2CDK5 | |
| SCHEMBL22828374 | 0.71 | STING1 (0.55) | NTRK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ROCK2 1545/4885DGAT1 1032/4885NTRK1 4073/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | ROCK2 2058/4885DGAT1 2738/4885NTRK1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.